Dr. Reddys Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 500124 | NSE: DRREDDY | Pharmaceuticals & Drugs | Large Cap

Dr. Reddys Lab Share Price

1,164.75 12.80 1.11%
as on 24-Feb'25 16:59

DeciZen - make an informed investing decision on Dr. Reddys Lab

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Dr. Reddys Laboratories stock performance -

P/E Ratio (CD):
18.09
Market Cap:
97,191.9 Cr.
52-wk low:
1,120
52-wk high:
1,420.2

Is Dr. Reddys Laboratories Ltd an attractive stock to invest in?

1. Is Dr. Reddys Laboratories Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr. Reddys Laboratories Ltd is a good quality company.

2. Is Dr. Reddys Laboratories Ltd undervalued or overvalued?

The key valuation ratios of Dr. Reddys Laboratories Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Dr. Reddys Laboratories Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Dr. Reddys Laboratories Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Dr. Reddys Lab:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Dr. Reddys Laboratories Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
ROCE % 22.7%19.6%9.8%8.2%13.7%11.1%15.5%14.6%26.2%26.9%-
Value Creation
Index
1.00.7-0.1-0.30.20.00.40.31.31.4-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 15,02315,56814,19614,28115,44817,51719,04821,54524,67028,01130,380
Sales YoY Gr.-3.6%-8.8%0.6%8.2%13.4%8.7%13.1%14.5%13.5%-
Adj EPS 26.828.515.711.42223.922.523.753.365.964.4
YoY Gr.-6.2%-45%-27%93%8.5%-6.1%5.7%124.6%23.6%-
BVPS (₹) 114.6146.3146.9150.5168186.5210.5229.2277.8337.2385.3
Adj Net
Profit
2,2822,4271,2979471,8301,9871,8681,9764,4375,4965,371
Cash Flow from Ops. 2,5243,2632,1441,8032,8702,9843,5702,8115,8884,543-
Debt/CF from Ops. 1.712.32.81.30.70.91.20.20.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7.2%12.6%13.7%13.5%
Adj EPS 10.5%24.5%43.2%23.6%
BVPS12.7%15%17%21.4%
Share Price 5.9% 13.5% 11.7% -9.6%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24TTM
Return on
Equity %
25.821.710.57.613.813.411.210.720.921.317.8
Op. Profit
Mgn %
23.425.817.516.520.614.120.317.526.228.327.4
Net Profit
Mgn %
15.215.58.96.411.911.39.89.21819.617.7
Debt to
Equity
0.40.30.40.40.30.10.20.20.10.1-
Working Cap
Days
187193212222214207213216212221153
Cash Conv.
Cycle
12212814013713012613213513112884

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 17.80%

Sales growth is growing at healthy rate in last 3 years 13.72%

Net Profit is growing at healthy rate in last 3 years 43.15%

Sales growth is good in last 4 quarters at 15.65%

No data to display

Latest Financials - Dr. Reddys Laboratories Ltd.

Standalone Consolidated
TTM EPS (₹) 62.1 64.4
TTM Sales (₹ Cr.) 21,485 30,380
BVPS (₹.) 332.6 385.3
Reserves (₹ Cr.) 27,674 32,066
P/BV 3.50 3.02
PE 18.75 18.09
From the Market
52 Week Low / High (₹) 1120.01 / 1420.20
All Time Low / High (₹) 1.25 / 1420.20
Market Cap (₹ Cr.) 97,192
Equity (₹ Cr.) 83.4
Face Value (₹) 1
Industry PE 37.5

Quarterly Results

 Mar'24 YoY Gr. Rt. %Jun'24 YoY Gr. Rt. %Sep'24 YoY Gr. Rt. %Dec'24 YoY Gr. Rt. %
Sales (₹ Cr.) 6,826 16.87,673 13.97,886 17.17,996 14.8
Adj EPS (₹) 78.5 36.383.5 -13 -83.117 2.4
Op. Profit Mgn % 26.83 58 bps27.76 -284 bps26.33 -349 bps28.43 -62 bps
Net Profit Mgn % 18.36 328 bps18.02 -271 bps16.62 -479 bps16.70 -234 bps

Management X-Ray of Dr. Reddys Lab:

Shareholding Pattern

JavaScript chart by amCharts 3.21.5
JavaScript chart by amCharts 3.21.5Promoters:26.64%Institutions:49.74%Non-Institutions:10.38%

Promoter's Holding & Share Pledging

JavaScript chart by amCharts 3.21.5Sep22Dec22Mar23Jun23Sep23Dec23Mar24Jun24Sep24Dec240%5%10%15%20%25%30%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Valuation of Dr. Reddys Lab

MRP
spaceLock icon
MOS
spaceLock icon%
DP
spaceLock icon
Base EPS
spaceLock icon
DPS
spaceLock icon
MRP: ₹ 0
DP: ₹0
Base EPS ₹:
DPS ₹:
MOS (%):
Expected EPS Growth Rate:
0%
Base 0%
50%
Expected Rate of Return:
0%
Base 0%
50%
Future PE:
0
Base 0
200
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max
YTD 1Y 3Y 5Y 10Y Max

Event Update

Login/Register to view analysis.

Analyst's Notes

Dr. Reddy's Laboratories: Sell Note - 27 Nov 2024

It is our opinion that the current valuations are ahead of the expected growth. The Price to Earnings Ratio of 19 masks the fact that a large part of the profit will be non-recurring after January 31st, 2026. The company’s TTM EBITDA Margin of 27% is significantly higher than its 10 year average of 21%, and a reversion to mean is expected. Based solely on a recurring rate of revenue, the adjusted P/E would be at least 30, while growth prospects seem low. 

The problems with the sustainability of earnings are due to challenges in North America. North America is the largest segment of the business, accounting for around half of the company’s sales. This segment has become the most profitable and highest growing segment over the last 2 years, mainly due to sales of Revlimid in the United States. Our estimates suggest that Revlimid sales account for a very large portion of the company’s current profits. The exclusivity for the drug ends on January 31st 2026, and the subsequent price erosion would lead to an overall reduction in sales and profits.

The problem is twofold: (a) the company needs to find a replacement for existing profits and (b) find a new source for growth by 31st January 2026. In our opinion, the company’s current pipeline is weaker than that of peers, which makes future growth prospects seem ambitious because replacing Revlimid sales and profits itself would be challenging due to the extremely high profitability of the drug.

Dr. Reddy’s Laboratories: Q4FY24 Result Update - 24 May 2024

ParticularsQ4FY24 (Rs.Cr)YoY(%) TrendComments
Revenue7114+12.65% 
EBITDA1831+19.29% 
EBITDA Margin (%)26%+145 bps 
PAT1310+36.45%Low Effective Tax Rate in Q4FY24

 

Dr. Reddy’s Laboratories Quarterly Call: Key Takeaways

  1. Exclusive Partnership with Nestle: The company has formed a JV with Nestle Health Sciences to bring their range of nutraceuticals to India. The contribution from this business should be visible FY27 onwards.
  2. Regulatory Scrutiny: The company has received a Complete Response Letter (CRL) from the USFDA regarding their Biologics License Application for a biosimilar rituximab, indicating that the application will not be approved in its present form. This highlights growth concerns.
  3. Research and Development: R&D investments for the quarter amounted to Rs. 688 crores, reflecting a 28% year-on-year increase. This growth was driven by the biosimilar products pipeline, along with development efforts in generics and novel oncology assets at Aurigene. The level of R&D for next year will be around 8.5% to 9%. Out of this, 20 is earmarked for biologics.
  4. Price Erosion: The company has started to face price erosion in the United States and Europe which are expected to impact sales of current products, excluding Revlimid.
  5. Guidance: The company maintains its long term guidance of 25% EBITDA Margins and 25% ROCE, along with double digit revenue growth.

 

We maintain our MRP of Rs. 5185.  

Dr. Reddy's Laboratories: Stock Pulse - 23 May 2024

About the Company

Dr Reddy’s is a leading Indian pharmaceutical company headquartered in Hyderabad, Telangana. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology and its major markets include – USA, India, Russia and CIS (Commonwealth of Independent States) countries, China, Brazil and Europe. The company’s main business segments are Global Generics, which includes sale of branded and unbranded generic drugs, and Pharmaceutical Services and Active Ingredients (PSAI), which majorly includes the sale of Active Pharmaceutical Ingredients (APIs).

North America is the largest market for the company’s generics, which accounts for 47% of the total revenue. This is due to the fact that the United States is the world’s largest market with a high GDP per capita leading to higher prices for drugs. Overall, the global generics business accounts for 88% of the total revenue, while PSAI accounts for 11%.

Financial Performance

The financial performance of pharmaceutical company tends to be volatile due to dependence on regulators, product launches, price erosion and price ceilings that may be applicable in various markets. The tables below highlight the volatility in financial performance.

As the table shows, the earnings per share between FY14 and FY24 have been extremely volatile. The period till FY16 marked the benefits of the patent cliff in the United States which led to the launch of various off patent drugs, while the FY17 and FY18 were marked by price erosion, distributor consolidation in the United States and problems regarding FDA facility inspections. Between FY19 and FY23, the company has been able to improve its performance by entering new markets, launching new products, and effective cost control measures. While such improvements have taken place, one must consider the sustainability of earnings given the cyclical nature of earnings. A key change in the company has been the appointment of Erez Israeli as COO in FY19 and CEO in FY20, who has helped make the company more efficient.

Understanding the Business

India: The company derives 17% of its revenue from India through the sale of branded generics. Revenues from India have grown at an annualised rate of 12% over the last 5 years. The company has made strategic investments like Cidmus to improve to cardiac portfolio while divesting certain non-core brands in the dermatology, paediatric, gynaecology, and urology segments.  The company aims to improve its contribution from chronic therapies, which stands at 35% currently.

Emerging Markets: Russia, Commonwealth of Independent States (CIS) and Romania accounted for 64% of the revenue from Emerging Markets in FY24. Many emerging markets are too small for domestic players due to the high research and development costs that would be associated with drug development and therefore depend on imports. India, and therefore Dr Reddy’s Laboratories, is a key exporter to such regions. However, geopolitical issues can have a severe impact on sales as well as the ability to supply such geographies. For example, Venezuela was a profitable emerging market until FY17 that has faced geopolitical and macroeconomic problems. As a result, business in this country had to be significantly curtailed due to the high risks. Additionally, foreign exchange remains a key risk for this business segment. 

Europe: Europe is the largest pharmaceutical market after the United States. The company has grown its revenue from Europe by 21% annually over the last 5 years. This has been achieved through the launch of new products, penetration in newer geographies while facing price erosion due to the competitive nature of the markets. Germany is the largest European market for the company.

North America: The large share of revenue from the United States is primarily responsible for the volatility in sales and profits. With the end of the patent cliff (a period in which a large number of key drugs lose patent protection) in the United States, 2017 and 2018 witnesses significant price erosion leading to a 20% fall in segment revenue over a two year period. The profitability and sales are highly dependent on patent expirations and the ability to compete through early launches. The company launched g-Revlimid in FY2023 through an early settlement with the innovator giving it a limited volume launch. This is largely responsible for the increase in profitability in FY23 and FY24 and is expected to continue until January 2026. Growth after 2026 is expected to come from biologics, as this segment will witness a large number of patent expirations during this period.

PSAI: While this division contributes 11% to the total revenue, the business has a significantly lower gross margin than the generic business. As a result, the overall growth in this segment has only been 4% annually over a 5 year period. Additionally, this business has a high volatility in its gross margins. Due to the lower overall gross margins from this business and the low revenue contribution, the overall impact of this segment on the business is manageable.

What are the growth and margin expectations?

Margins: PAT margins have improved from 9% in FY17 to 20% for FY24. As the table above shows, the major reason for the improvement in EBITDA and PAT Margins is the reduction in R&D and SG&A as a percentage of revenues. R&D has not only declined from 14% in FY17 to 8% for FY24, the absolute spend on R&D has also declined over time until FY24, when it increased. Additionally, SG&A expenditure as a percentage of revenues has fallen from 33% in FY17 to 28% for FY24. While there has been an improvement in gross margins as well, the sustainability of the margins is highly dependent on successful new launches while maintaining the risk of price erosion. 

Overall, the long term EBITDA margins are guided to be around the 25% range as gross margins would fluctuate while other overhead costs are likely to be maintained at the current percentages. 

Growth: India, Emerging Markets and Europe are expected to have growth in double digits over the next few years even though fluctuations are expected on a yearly basis. This expectation is based on the strong positioning of the company in these markets. While Europe does maintain the risk of price erosion, new product launches in this segment and overall low contribution to revenue would not have a strong impact on overall growth expectations.

The growth in the North American market in the previous year is primarily attributable to the launch of g-Revlimid. Growth in Revlimid is expected till January 31st, 2026 when the company loses exclusivity. Due to a structural change in the North American market, the focus has shifted towards biologics, which are more complex and difficult to replicate. This would lead to lower growth rates for chemical generics than that witnessed in the previous cycle, but overall growth would still remain high. The company has begun development of biologics with significant expected launches between FY27 and FY30 which suggests a long term growth potential for the company. However, the company currently faces regulatory challenges in its biologics division, which might hinder the growth of this segment.

 

Dr Reddys Laboratories: Q2FY24 result update - 04 Nov 2023

            

Particulars

Q2FY24 (Rs. Crs)

YoY Trend

Comments

Revenue

6,903

+9%

On back of 9% growth in global generics and 17% in pharma services segment 
EBITDA

2,008

+6%

 
EBITDA Margin

29%

-90 bps

No major change 
PAT

1,482

+33%

Excluding other income PAT growth at 4% YoY 

Good results, plans to focus on licensing and collaborating with partners to bring innovation to India and strengthen its presence in the generic business.

Dr Reddy's Laboratories: Q1FY24 Result Update - 28 Jul 2023

Particulars

Q1FY24

YoY trend

Comment

Revenue

6,758

+29%

Growth across generics, pharmaceutical services and active ingredients segments    

EBITDA

2,062

+120%

 

EBITDA Margin

31%

+1252 bps

Favourable product mix and foreign exchange benefits as well as operating leverage played out  

PAT

1,405

+18%

 

Good performance on uptick in exports across North America business and favorable seasonality in the Russia business.

 

Dr. Reddys Laboratories: Q3FY23 Result Update - 30 Jan 2023

Market Cap Rs. 71,995cr

CMP Rs. 4,321 | PE 19.8x TTM

Results

INR Cr.

Y-o-Y Growth

Comments

Revenue

6,770

27.3%

Revenue growth of 27.3% YoY led by strong growth in USA (64% YoY), Emerging Markets (14% YoY) and India (10% YoY)

Gross Profit

4,009

40.1%

Gross margins came in at 59.2% (vs 53.8% in Q3FY22) primarily driven by new product launches with higher margin profiles, favourable product and favourable forex movements

EBITDA

2,082

69.9%

EBITDA margins came in at 30.8% (vs 23% in Q3FY22) due higher gross margins and relative reduction in SG&A expenses

Click here for 10 year X-ray

 

Key Highlights:

  • US sales growth driven by launch of gRevlimid (revenue of ~$140mn in Q3), 5 new launches and favourable forex movements, which was partly offset by price erosion in some molecules.
  • Emerging markets growth was primarily due to the strong growth experienced in Russia (45% YoY). It launched 29 products in Q3.
  • India sales growth was led by price hikes and 2 new product launches, although there was volume contraction in certain molecules.

Management Outlook:

  • Management expects contribution from gRevlimid to fluctuate quarterly but to remain meaningful on annual basis. It also expects ex-gRevlimid business in the US to grow in single digits.
  • Management expects Indian business to sustain double-digit growth through a combination of organic route, product innovation, investments in marketing and divestment of legacy brands.
  • The company is looking to file double-digit number of products in China (40-50 over the next 3 years). Meaningful ramp up in growth of China operations  are expected by H2FY24 by the management.
  • Management has guided EBITDA margins and RoCE to be ~25%.

Key Ratios of Dr. Reddys Lab

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Company Name CMP(₹)
Change ₹(%)
Market Cap
Net Sales (₹ Cr.)
Latest EPS (₹)
Net Profit Margin %
Latest P/E
Latest P/BV
Sun Pharma Inds. 1,639.6 -3.5 (-0.2%) Large Cap 48,497 47.7 20.9 34.4 5.5
Dr. Reddys Lab 1,164.8 12.8 (1.1%) Large Cap 28,011 64.4 19.6 18.1 3
Cipla 1,476.6 2.3 (0.2%) Large Cap 25,774 61.8 15.6 23.9 4
Zydus Lifesciences 890.6 5.5 (0.6%) Large Cap 19,547 45.1 19.3 19.8 3.9
Torrent Pharma 3,010.5 -25.3 (-0.8%) Large Cap 10,728 55 14.8 54.7 12.7
Divis Lab 5,704 -44.8 (-0.8%) Large Cap 7,845 77.9 20.2 73.3 10.6

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Sales15,02315,56814,19614,28115,44817,51719,04821,54524,67028,011
Operating Expenses 11,53011,98311,72411,93012,27015,04715,17817,77818,32120,078
Manufacturing Costs2,3382,1722,2172,0761,7641,7601,8951,9932,2162,621
Material Costs3,7863,7593,6974,0404,4955,5546,0797,4427,6588,209
Employee Cost 2,9453,1173,1073,2153,3563,3803,6303,8864,6475,030
Other Costs 2,4612,9362,7042,6002,6554,3523,5744,4573,8004,218
Operating Profit 3,4943,5852,4722,3513,1782,4703,8703,7676,3497,933
Operating Profit Margin (%) 23.3%23.0%17.4%16.5%20.6%14.1%20.3%17.5%25.7%28.3%
Other Income 2752951721553386212914851,056894
Interest 10983637989989796143171
Depreciation 7609391,0271,0771,1351,1631,2291,1651,2501,470
Exceptional Items 0000000000
Profit Before Tax 2,9002,8591,5541,3502,3361,8862,8843,0616,0497,201
Tax 563751297438386-1409328791,5411,623
Profit After Tax 2,3362,1081,2579121,9502,0261,9522,1834,5075,578
PAT Margin (%) 15.6%13.5%8.9%6.4%12.6%11.6%10.2%10.1%18.3%19.9%
Adjusted EPS (₹)27.425.015.611.423.524.423.526.254.166.9
Dividend Payout Ratio (%)15%16%26%35%17%21%21%23%15%12%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24

Equity and Liabilities

Shareholders Fund 9,76312,47912,18212,48913,94415,49517,51519,06923,14028,124
Share Capital 85858383838383838383
Reserves 9,67712,39412,09912,40613,86115,41217,43218,98623,05728,040
Minority Interest0000000000
Debt3,6173,3404,9085,0653,4131,7842,9443,2838671,871
Long Term Debt1,4321,0695452,5092,200130630575128599
Short Term Debt2,1862,2724,3632,5561,2131,6532,3152,7087391,272
Trade Payables8679071,0571,3351,3671,5251,8112,2662,2682,614
Others Liabilities 4,1063,0672,9923,1153,3103,2023,2783,8525,3045,197
Total Liabilities 18,35319,79421,13822,00422,03422,00525,54828,47031,58037,806

Fixed Assets

Gross Block12,57415,02015,93217,43618,04819,33621,88723,09625,56728,062
Accumulated Depreciation7,1708,4579,00210,46810,85712,48513,63214,89516,34817,636
Net Fixed Assets5,4046,5636,9316,9687,1916,8508,2558,2029,21910,426
CWIP 5297723,3253,4712,9341,5351,5651,2931,0301,419
Investments 2,2483,8332,1102,2982,5872,6782,2122,6164,9864,931
Inventories2,5702,5582,8532,9093,3583,5074,5415,0884,8676,355
Trade Receivables4,1014,1253,7994,0533,9875,0284,9646,6767,2498,030
Cash Equivalents 1,8724923872642232052,0792,4191,7301,728
Others Assets1,6291,4501,7352,0421,7552,2021,9332,1752,4994,917
Total Assets 18,35319,79421,13822,00422,03422,00525,54828,47031,58037,806

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Cash Flow From Operating Activity 2,5243,2632,1441,8032,8702,9843,5702,8115,8884,543
PBT 2,9002,8591,5541,3502,3361,8862,8843,0616,0497,201
Adjustment 1,6541,1081,6871,6258352,5632,0872,3341,6961,365
Changes in Working Capital -1484-3-520-897184-754-829-1841-786-2018
Tax Paid -546-701-577-276-484-711-572-744-1,071-2,005
Cash Flow From Investing Activity -2,265-2,039-1,840-1,488-773-492-2,266-2,639-4,137-4,028
Capex -1,514-1,473-4,089-1,090-623-573-1,248-1,573-1,878-2,635
Net Investments -831-6952,187-425-228-21-1,140-1,153-2,337-1,572
Others 811286127781021228778178
Cash Flow From Financing Activity -433-1,700-369-444-2,133-2,516-30-242-2,686-376
Net Proceeds from Shares 10000027331681
Net Proceeds from Borrowing -373-1,171-5221,891-6-2,2926000
Interest Paid -109-92-92-133-161-161-132-135-185-227
Dividend Paid -359-411-339-332-332-331-415-415-498-665
Others 407-27584-1,870-1,634268484274-2,019435
Net Cash Flow -174-477-65-129-35-241,275-70-936139
PARTICULARSMar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24
Ratios
ROE (%)26.6318.9510.27.414.7513.7611.8211.9321.3621.76
ROCE (%)22.719.559.778.2113.6611.1215.4914.5926.2226.86
Asset Turnover Ratio0.880.820.690.660.70.80.80.80.820.81
PAT to CFO Conversion(x)1.081.551.711.981.471.471.831.291.310.81
Working Capital Days
Receivable Days909610210095949699103100
Inventory Days60607074747277827473
Payable Days85869710811095100100108109

Dr. Reddys Laboratories Ltd Stock News

Dr. Reddys Laboratories Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Dr. Reddys Lab on 24-Feb-2025 16:59 is ₹1,164.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 24-Feb-2025 16:59 the market cap of Dr. Reddys Lab stood at ₹97,191.9.
The latest P/E ratio of Dr. Reddys Lab as of 24-Feb-2025 16:59 is 18.75.
The latest P/B ratio of Dr. Reddys Lab as of 24-Feb-2025 16:59 is 3.50.
The 52-week high of Dr. Reddys Lab is ₹1,420.2 and the 52-week low is ₹1,120.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Dr. Reddys Lab is ₹21,485 ( Cr.) .

About Dr. Reddys Laboratories Ltd

Dr. Reddy’s Laboratories Limited commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas. The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and on the New York Stock Exchange in the United States.

Business area of the company

The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.

Products

  • Generics
  • Over-the-counter
  • APIs (Active Pharmaceutical Ingredients)
  • Biologics
  • Differentiated Formulations

Core Businesses

Pharmaceutical services & active ingredients

  • Global leader in integrated development, manufacturing and supply of APIs.
  • Contract research, development and manufacturing services.

Global Generics

  • Finished dosage businesses in distribution-driven unbranded as well as detailing-driven branded markets.
  • North America, Europe, India, China, Russia & CIS countries are key markets in this segment.

Proprietary Products

  • Developing differentiated formulations that present significantly enhanced benefits in terms of efficacy, ease of use, and the resolution of unmet patient needs.

Awards & Recognitions

  • India’s Best Managed Boards by Mint and Aon Hewitt and by Economic Times and Hays in their respective studies.
  • India’s Best Companies to Work For in the Biotechnology and Pharmaceuticals sector by Great Place To Work Institute.
  • ‘Best Places to Work’ in 2017 in New Jersey by NJBIZ.
  • Global Generics & Biosimilar Award 2018 for CSR initiative of the year
  • India Pharma Corporate Social Responsibility (CSR) programme of the year Award 2018 by Department of Pharmaceuticals, Government of India.
  • Dr. Reddy’s ranked among the top 10 in the Forbes China 2018 list of leading Indian Companies in China.
  • Dr. Reddy’s inclusion in the 2019 Bloomberg Gender-Equality Index.
  • Global Generics & Biosimilars Award 2019: API supplier of the Year at the 6th Annual Global Generics & Biosimilars Awards.
  • Winner of Golden Peacock International Award for Sustainability for the year 2019.

Milestones

  • 1984: The birth of a dream
  • 1991: From molecules to affordable medicines
  • 1995: Expanding to reach patients in other countries
  • 2001: Spreading wings globally
  • 2007: Accelerating access to expensive therapies
  • 2010: From medicines to health
  • 2012: Strengthening capabilities
  • 2014: Re-dedicating to patient-centricity
  • 2015: Dr. Reddy’s Laboratories signs commercialization deal with Hatchtech
  • 2016: Dr. Reddy’s completes acquisition of product portfolio from TEVA
  • 2017: Dr. Reddy's expands commercial operations in Europe
  • 2018: Dr. Reddy's Laboratories announces the launch of Tetrabenazine Tablets in the U.S. Market
  • 2019: Dr. Reddy’s Laboratories enters Nutrition Segment with Celevida in India
  • 2020: Dr. Reddy’s Laboratories joins Science Based Targets initiative (SBTi) and sets 2030 GHG emission targets
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Loading...
Hold on